共 50 条
Risk of De Novo Inflammatory Bowel Disease in Patients With Psoriasis and Psoriatic Arthritis Treated With IL-17A Inhibitors: A Population-Based Study
被引:0
作者:
Alsakarneh, Saqr
[1
]
Al Ta'ani, Omar
[2
]
Aburumman, Razan
[3
]
Mikhail, Inas
[4
]
Hashash, Jana G.
[4
]
Farraye, Francis A.
[4
]
机构:
[1] Univ Missouri Kansas City, Dept Med, Kansas City, MO USA
[2] Allegheny Hlth Network, Dept Med, Pittsburgh, PA 15222 USA
[3] Henry Ford Hosp, Dept Med, Detroit, MI USA
[4] Mayo Clin, Div Gastroenterol & Hepatol, Jacksonville, FL USA
关键词:
IL-17;
inhibitors;
inflammatory bowel disease;
Secukinumab;
D O I:
10.1111/apt.70139
中图分类号:
R57 [消化系及腹部疾病];
学科分类号:
摘要:
IL-17 inhibitors effectively treat psoriasis and psoriatic arthritis but may increase the risk of inflammatory bowel disease (IBD). We assessed their association with IBD compared to apremilast. Utilising the TriNetX database, we analysed patients with psoriasis or ankylosing spondylitis initiating IL-17 inhibitors or apremilast. We used propensity score matching and Cox models to estimate IBD risk. Among 13,216 matched patients per group, 142 developed IBD with IL-17 inhibitors versus 60 with apremilast (aHR = 2.50, 95% CI: 1.85-3.39). IL-17 inhibitors increase IBD risk, necessitating careful patient selection and monitoring.
引用
收藏
页码:72 / 76
页数:5
相关论文
共 50 条